0001209191-21-069350.txt : 20211213 0001209191-21-069350.hdr.sgml : 20211213 20211213203937 ACCESSION NUMBER: 0001209191-21-069350 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20211209 FILED AS OF DATE: 20211213 DATE AS OF CHANGE: 20211213 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Quinn Anthony G. CENTRAL INDEX KEY: 0001532219 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37722 FILM NUMBER: 211489463 MAIL ADDRESS: STREET 1: C/O AEGLEA BIOTHERAPEUTICS, INC. STREET 2: 901 S. MOPAC EXPWY, STE. 250 CITY: AUSTIN STATE: TX ZIP: 78746 FORMER NAME: FORMER CONFORMED NAME: Quinn Anthony DATE OF NAME CHANGE: 20111007 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aeglea BioTherapeutics, Inc. CENTRAL INDEX KEY: 0001636282 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 464312787 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 805 LAS CIMAS PARKWAY STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78746 BUSINESS PHONE: (512) 942-2935 MAIL ADDRESS: STREET 1: 805 LAS CIMAS PARKWAY STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78746 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-12-09 0 0001636282 Aeglea BioTherapeutics, Inc. AGLE 0001532219 Quinn Anthony G. 805 LAS CIMAS PARKWAY SUITE 100 AUSTIN TX 78746 1 1 0 0 President & CEO Common Stock 2021-12-09 4 P 0 43108 3.70 A 318269 D Common Stock 2021-12-10 4 P 0 10526 3.75 A 328795 D Common Stock 266295 I By trusts The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.55 to $3.85 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4. Includes 963 shares of common stock acquired by the Reporting Person on August 15, 2020, 917 shares of common stock acquired by the Reporting Person on February 17, 2021, and 1,107 shares of common stock acquired by the Reporting Person on August 15, 2021 pursuant to the Issuer's employee stock purchase plan. The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.62 to $3.80 per share, inclusive. Includes 57,450 shares of common stock held by the Anthony G. Quinn Irrevocable Trust of 2018 and 208,845 shares of common stock held by the Quinn Family Irrevocable Trust of 2021(together, the "Trusts"). The Reporting Person's spouse is trustee of the Trusts. /s/ Steven Weber, by power of attorney 2021-12-13 EX-24 2 poa.txt POA DOCUMENT POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Jonathan Alspaugh, Steven Weber and James Kastenmayer, and each of them, as the undersigned's true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as a representative of Aeglea BioTherapeutics, Inc. (the "Company"), any and all Form ID, or Form 3, 4 or 5 reports and any amendments thereto required to be filed by the undersigned in accordance with Section 16(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and the rules thereunder with respect to transactions in the Company's securities; (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form ID, or Form 3, 4 or 5 report and any amendments thereto and timely file such report with the U.S. Securities and Exchange Commission and any stock exchange or similar authority; and (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned, pursuant to this Power of Attorney, shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in his or her discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform each and every act and thing whatsoever requisite, necessary, and proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or his or her substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that no such attorney-in-fact, in serving in such capacity at the request of the undersigned, is hereby assuming, nor is the Company hereby assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Form 3, 4 or 5 reports with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 13th day of December, 2021. /s/ Anthony G. Quinn Name: Anthony G. Quinn